Nutriband Revenue, Net Income & 10-K Summary

Company overview

Legal status: Nevada corporation, formed January 2016. Corporate headquarters in Orlando, Florida.
Primary business: development of transdermal pharmaceutical products, centered on the AVERSA abuse-deterrent transdermal technology.

Revenue is generated through services provided by two subsidiaries:
- Pocono Pharmaceuticals (operating as Active Intelligence): contract manufacturing for health, wellness, and over‑the‑counter pharmaceutical customers.
- 4P Therapeutics: contract research and development services for pharmaceutical and medical‑device customers.
4P Therapeutics’ services are expected to be limited in revenue while the company advances its development programs, consistent with an early‑stage profile.

Pocono Pharmaceuticals: contract manufacturer with a manufacturing facility in Cherryville, North Carolina.
4P Therapeutics: provides contract R&D services for life sciences customers.
In 2020 the company acquired Pocono Coated Products assets, including ownership of Active Intelligence LLC (now part of Pocono).
The acquisition of 4P Therapeutics brought AVERSA‑related technology and development programs into Nutriband’s portfolio.

Core technology: AVERSA abuse‑deterrent transdermal products.
- AVERSA™ Fentanyl: lead program — an abuse‑deterrent fentanyl transdermal system intended to reduce abuse and accidental exposure when used as a patch.
- Additional programs under consideration: AVERSA™ Buprenorphine and AVERSA™ Methylphenidate.
Long‑term strategy: apply AVERSA technology to other approved transdermal drugs and pursue generic or improved transdermal products.

Primary regulatory route for AVERSA Fentanyl: 505(b)(2) NDA pathway, referencing an existing fentanyl patch and a Phase 1 human abuse‑potential study to support abuse‑deterrent claims.
The company is planning a Phase 1 abuse‑potential study to support an NDA submission and is following standard regulatory elements (IND, NDA, CMC).
FDA engagement: in October 2025 Nutriband completed a Type C meeting with FDA on Chemistry, Manufacturing, and Controls (CMC) for AVERSA Fentanyl. Topics included batch validation, stability, specifications, and abuse‑deterrence testing plans.
The program may qualify for expedited review under certain conditions, though that outcome is not guaranteed.

AVERSA technology is covered by patents in the United States and in 45–46 other countries.
U.S. patents include: 11,246,840 (2022); 11,759,431 (2023); 12,318,492 (2025), with protection through at least 2035.
A provisional U.S. patent was filed on October 3, 2025 to strengthen protection for improved aversive formulations and coating methods; potential extensions could extend coverage to 2046 if granted.
Trademark activity includes registered NUTRIBAND marks and a filed AVERSA wordmark. Nutriband engaged Brand Institute to develop the worldwide brand name for AVERSA Fentanyl.
IP strategy uses patent protection, trade secrets, and ongoing prosecution in key jurisdictions.

Exclusive product development partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery):
- Initial agreement signed January 2024 to develop AVERSA Fentanyl using Kindeva’s FDA‑approved fentanyl patch.
- A February 13, 2025 addendum established a long‑term exclusive development partnership with shared development costs and milestone payments.
- The program includes preclinical and clinical studies to demonstrate abuse deterrence, with a regulatory path through a 505(b)(2) NDA.
The collaboration uses Kindeva’s patch platform for AVERSA Fentanyl and may support future AVERSA products.

Corporate offices in Orlando: leased at $2,500 per month.
Cherryville, North Carolina manufacturing facility: leased at $3,000 per month under a three‑year extension effective February 1, 2025.

Management ownership: officers and a group including Gareth Sheridan (CEO), Serguei Melnik (President), and Dr. Alan Smith (COO) collectively own about 49.88% of common stock (as of April 28, 2026).
The company relies on key personnel, and the loss of those individuals could materially affect operations.

Ongoing litigation: Joseph Gunnar, LLC and Lucosky Brookman LLP v. Nutriband, Inc., in New York state court. Nutriband has filed counterclaims and the case is in discovery. A proposed settlement offer was previously extended and not accepted.

Nutriband is focused on advancing AVERSA‑based transdermal products, starting with AVERSA Fentanyl and expanding to other AVERSA candidates and transdermal opportunities.
The company depends on partnerships (notably Kindeva) for development and manufacturing, and combines internal R&D with contract research services via 4P Therapeutics.
As an early‑stage enterprise, Nutriband emphasizes the need to secure capital to support product development and commercialization, supported by a portfolio of intellectual property intended to underpin future market entry.